We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 3B22 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects IRF7. It targets an epitope within 22 amino acids from the N-terminal half.

KLH-conjugated linear peptide corresponding to 22 amino acids from the N-terminal half of human IRF7.

Quality Control Testing

Evaluated by Western Blotting in rat lung tissue lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected IRF7 in rat lung tissue lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected IRF7 in BDCM (B-cell with Dendritic Cell Morphology) cell lysate.

Affinity Binding Assay: A representative lot of this antibody bound with IRF7 peptide at least one hundred thousand-fold (100,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected IRF7 in human thymus tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected IRF7 in BDCM (B-cell with Dendritic Cell Morphology) cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Interferon regulatory factor 7 (UniProt: Q92985; also known as IRF-7) is encoded by the IRF7 gene (Gene ID: 3665) in human. IRF7 is a transcription factor belonging to the interferon regulatory factor (IRF) family. It contains a conserved IRF domain responsible for DNA binding and a regulatory domain that influences its transcriptional activity. IRF7 can form homodimers and heterodimers with other IRF family members, enhancing its functional diversity. IRF7 plays a crucial role in the immune response, particularly in the regulation of type I interferons (IFNs), such as IFN- and IFN-β. It is activated in response to viral infections and other stimuli, leading to the transcription of genes involved in the antiviral response, immune signaling, and inflammation. IRF7 is essential for the amplification of the type I interferon response. IRF7 is expressed in various tissues, with higher levels observed in immune cells, such as plasmacytoid dendritic cells (pDCs), which are key producers of type I interferons. Its expression can be induced by viral infections and other pro-inflammatory signals. IRF7 is primarily localized in the cytoplasm under resting conditions. Upon activation, it translocates to the nucleus, where it binds to specific DNA sequences in the promoters of interferon-stimulated genes (ISGs) to regulate their expression. Dysregulation of IRF7 has been implicated in various diseases, including autoimmune disorders, cancers, and viral infections. In autoimmune diseases like systemic lupus erythematosus (SLE), aberrant IRF7 activity can lead to excessive type I interferon production, contributing to inflammation and tissue damage. Additionally, IRF7 is involved in the host response to viral infections, making it a potential target for therapeutic interventions. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.